| Website | aileronrx.com |
| Category | BioTech |
| Phone | 617-995-0900 |
| info@aileronrx.com | |
| Employees | |
| Founded | 2005 |
| Description | biotechnology company |
| TOTAL | $69.5M |
| FUNDING TOTAL | $69.5M |
| Series A, 12/06 Apple Tree Partners Novartis Venture Funds | $7M |
| Series B, 4/08 Novartis Venture Funds Apple Tree Partners | $10.5M |
| Series D, 6/09 SR One Excel Medical Ventures Apple Tree Partners Lilly Ventures Roche Venture Fund Novartis Venture Funds | $40M |
| Series D, 1/13 Apple Tree Partners Excel Venture Management Lilly Ventures Novartis Venture Funds Roche Venture Fund SR One | $12M |
Aileron Therapeutics, based in Cambridge, Massachusetts, is a biopharmaceutical company that was founded in 2005 to develop and advance a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution, or “scaffold” for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. The ability to target and regulate these control points affords the unique opportunity to exploit potentially thousands of currently “undruggable” cellular targets with applications in all human diseases.
Aileron’s proprietary technology locks peptides into their biologically active shape, mimicking the structures found in nature, and ultimately endows the peptide with unique properties, including efficient cell penetration, high affinity binding to large target protein surfaces and excellent stability within the body.
